[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Flox Camacho A, Hernández Hernández F, Salguero Bodes R, Sánchez Pérez I, Carbonell Porras A, Tascón Pérez J: [Primary cardiac lymphoma: diagnosis by transjugular biopsy]. Rev Esp Cardiol; 2003 Nov;56(11):1141-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: diagnosis by transjugular biopsy].
  • Primary cardiac lymphoma, defined as a non-Hodgkin's lymphoma involving only the heart and pericardium, is an extremely rare malignancy.
  • It should be suspected in patients with a heart mass and heart failure, unexplained refractory pericardial effusion or rhythm disturbances.
  • Transvenous intracardiac tumor biopsy under fluoroscopic or transesophageal echocardiographic guidance, is a minimally invasive technique which makes definite diagnosis possible.
  • We describe a patient in whom primary cardiac lymphoma was diagnosed by this technique.
  • Seven months after diagnosis and treatment with standard chemotherapy, the patient remained free of disease.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Echocardiography, Doppler. Fluoroscopy. Humans. Jugular Veins / pathology. Jugular Veins / radiography. Male. Middle Aged. Pericardial Effusion / etiology. Pericardial Effusion / ultrasonography. Pericardiectomy. Prednisone / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14622547.001).
  • [ISSN] 0300-8932
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Wethal T, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A: Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer; 2009 Aug 18;101(4):575-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study.
  • PURPOSE: Hodgkin's lymphoma survivors (HLSs) have an elevated risk for cardiovascular diseases that appear several years after radiotherapy.
  • This study examined the time-dependent development and evolution of valvular and myocardial function related to treatment with mediastinal radiotherapy and anthracyclines in HLSs.
  • PATIENTS AND METHODS: In 1993, echocardiography was performed in 116 HLSs median 10 years (range 6-13 years) after treatment with mediastinal radiotherapy.
  • In 2005-2007, 51 of 57 invited patients were included in a second echocardiographic study - median 22 years (range 11-27 years) after treatment.
  • RESULTS: The second echocardiographic study demonstrated that 10 out of 27 (37%) patients with only mild or no aortic or mitral regurgitation in 1993 had developed moderate regurgitation in either or both the aortic or mitral valve.
  • Of the 24 patients with moderate (n=23) or severe (n=1) regurgitation in the aortic or mitral valve in 1993, 8 (33%) had progressed to severe regurgitation, developed moderate regurgitation in a previously normal or mild regurgitant valve or had received valvular replacement.
  • In total, of all patients, 20 (39%) had developed mild to severe aortic stenosis and 3 patients had received valvular replacement.
  • CONCLUSION: Given the progressive nature of valvular dysfunction and left ventricular remodelling 20-30 years after diagnosis, we recommend life-long cardiological follow-up of HLSs treated with mediastinal radiotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Heart Valve Diseases / etiology. Heart Ventricles / pathology. Hodgkin Disease / therapy. Mediastinal Neoplasms / therapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / adverse effects. Aortic Valve / drug effects. Aortic Valve / radiation effects. Echocardiography. Humans. Middle Aged. Mitral Valve / drug effects. Mitral Valve / radiation effects. Neoplasm Staging. Survivors. Ventricular Remodeling / drug effects. Ventricular Remodeling / radiation effects. Young Adult

  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Oct;213(1):167-72 [10540657.001]
  • [Cites] Eur Heart J. 2009 Feb;30(3):346-55 [19010796.001]
  • [Cites] J Am Coll Cardiol. 2001 Mar 1;37(3):761-5 [11693749.001]
  • [Cites] Med Phys. 2002 Oct;29(10):2391-403 [12408314.001]
  • [Cites] J Am Soc Echocardiogr. 2003 Jul;16(7):777-802 [12835667.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] Pharmacol Toxicol. 2003 Sep;93(3):105-15 [12969434.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):820-8 [14990637.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [Cites] Catheter Cardiovasc Interv. 2004 Oct;63(2):247-50 [15390239.001]
  • [Cites] Heart. 1996 Jun;75(6):591-5 [8697163.001]
  • [Cites] N Engl J Med. 1998 Sep 24;339(13):900-5 [9744975.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3592-600 [9817280.001]
  • [Cites] Am J Cardiol. 1999 Mar 15;83(6):897-902 [10190406.001]
  • [Cites] Circulation. 1999 Aug 10;100(6):635-41 [10441101.001]
  • [Cites] N Engl J Med. 2005 Jan 6;352(1):20-8 [15635109.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):561-78 [16351632.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):718-25 [16353211.001]
  • [Cites] Coron Artery Dis. 2006 Mar;17(2):145-51 [16474233.001]
  • [Cites] J Am Coll Cardiol. 2006 Aug 1;48(3):e1-148 [16875962.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):43-9 [17194904.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):186-7 [17284708.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):206-14 [17284715.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] Eur J Heart Fail. 2007 Apr;9(4):409-14 [17067854.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1916-27 [17989384.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):429-47 [11139373.001]
  • (PMID = 19623176.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2736805
  •  go-up   go-down


3. Chin JY, Chung MH, Kim JJ, Lee JH, Kim JH, Maeng IH, Jung SY, Hwang HJ, Lee JB, Youn HJ: Extensive primary cardiac lymphoma diagnosed by percutaneous endomyocardial biopsy. J Cardiovasc Ultrasound; 2009 Dec;17(4):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive primary cardiac lymphoma diagnosed by percutaneous endomyocardial biopsy.
  • Primary cardiac lymphoma (PCL) is an extranodal non-Hodgkin's lymphoma exclusively located in the heart and/or pericardium.
  • Although echocardiography, computed tomography (CT) scan, magnetic resonance image (MRI) are the mainly used imaging techniques to detect cardiac tumors, pathologic examination is always required to confirm the diagnosis.
  • Diagnosis of PCL is difficult due to non-specific clinical manifestations and requires invasive approach to get histopathologic evidence.
  • While surgery with systemic chemotherapy or in combination with irradiation has been attempted, the only effective treatment is chemotherapy.
  • We report on a 42-year-old woman who is diagnosed histopathologically as PCL by cardiac catheterization assisted percutaneous endomyocardial biopsy and treated successfully by anthracycline based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ J. 2009 Feb;73(2):381-3 [19057087.001]
  • [Cites] Jpn J Radiol. 2009 Jul;27(6):243-6 [19626410.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):6003-5 [19029409.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1344-50 [17721189.001]
  • [Cites] Am J Clin Oncol. 1991 Apr;14(2):142-5 [2028920.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):781-8 [15160956.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):456-61 [12447675.001]
  • [Cites] Yonsei Med J. 2001 Aug;42(4):451-6 [11519090.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1497-506 [9338475.001]
  • [Cites] Br J Haematol. 2006 Aug;134(4):356 [16882130.001]
  • (PMID = 20661340.001).
  • [ISSN] 2005-9655
  • [Journal-full-title] Journal of cardiovascular ultrasound
  • [ISO-abbreviation] J Cardiovasc Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2889391
  • [Keywords] NOTNLM ; Cardiac tamponade / Non-Hodgkin's lymphoma / Pericardial effusion
  •  go-up   go-down


Advertisement
4. Iwahashi N, Nakatani S, Kakuchi H, Yamagishi M, Fukuchi K, Ishida Y, Hirooka K, Koretsune Y, Ueta C, Shirasaka T, Kitakaze M: Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J; 2005 Feb;69(2):243-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extensive cardiac and extracardiac involvement shown by various imaging modalities, including echocardiography and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), suggested that she was in the critical stage of non-Hodgkin's lymphoma (NHL).
  • AIDS was treated by highly active-antiretroviral therapy and the NHL was treated by a combination of rituximab-cyclophosphamide-vincristine-doxorubicine-predonisolone.
  • After 6 cycles of chemotherapy, she was in complete remission.
  • In the present case, the cardiac tumor was detected by echocardiography and treated with appropriate chemotherapy.
  • Early diagnosis and prompt treatment may improve a patient's prognosis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Diagnostic Imaging. Echocardiography. Female. Humans. Positron-Emission Tomography. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671621.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


5. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Cho JG, Ahn YK, Cho SH, Lee JJ, Chung IJ, Park MR, Kim HJ, Jeong MH, Park JC, Kang JC: A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci; 2002 Aug;17(4):549-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of secondary myocardial lymphoma presenting with ventricular tachycardia.
  • Malignant lymphoma can involve the cardiac cavity or myocardium as a mass.
  • Clinical symptoms of its cardiac involvement are usually absent or nonspecific, making the diagnosis of the cardiac involvement very difficult before death.
  • We experienced a patient with secondary myocardial non-Hodgkin's lymphoma presenting with sustained ventricular tachycardia (VT) as a primary clinical problem.
  • Physical examination revealed rapid heart beat with variable intensity of the first heart sound and soft mass in the lower abdomen.
  • Cytological examination of aspirated pericardial fluid and percutaneous needle biopsy of the abdominal mass revealed a diffuse large cell type non-Hodgkin's lymphoma.
  • Myocardial masses and ventricular tachycardia resolved with chemotherapy using cyclophosphamide, adriamycin, vincristine and prednisone regimen.
  • [MeSH-major] Heart Neoplasms / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Myocardium / pathology. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172054.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054895
  •  go-up   go-down


7. Giuliante F, Sarno G, Ardito F, Pierconti F: Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge. Tumori; 2009 May-Jun;95(3):374-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge.
  • PATIENT CASE: A 26-year-old male patient with a previous history of radiochemotherapy treatment for Hodgkin's lymphoma was referred to our unit with a histological and radiological diagnosis of primary hepatic leiomyosarcoma.
  • Shortly before referral the lesion had grown to 7.8 cm, associated with two smaller lesions in segments VIII and III, and a diagnosis of hepatic leiomyosarcoma was made at biopsy.
  • This was followed by rapid progression of the disease, in spite of transient stabilization under gemcitabine treatment.
  • Octreotide was also administered after the detection of elevated chromogranin A in serum.
  • CONCLUSIONS: The challenges and peculiarities of this case are related to the rarity of the tumor, its accidental discovery without immediate suspicion of its nature, its very aggressive behavior that was only partly controlled by chemotherapy, and the unusual expression of a neuroendocrine phenotypic feature with high serum chromogranin A levels.
  • [MeSH-minor] Adult. Fatal Outcome. Hepatectomy. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688980.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Johri A, Baetz T, Isotalo PA, Nolan RL, Sanfilippo AJ, Ropchan G: Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. Can J Cardiol; 2009 Jun;25(6):e210-2
Genetic Alliance. consumer health - Superior vena cava syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome.
  • Primary cardiac lymphomas are rare extranodal lymphomas that should be distinguished from secondary cardiac involvement by disseminated non-Hodgkin's lymphoma.
  • Cardiac lymphomas often mimic other cardiac neoplasms, including myxomas and angiosarcomas, and often require multimodality cardiac imaging, in combination with endomyocardial biopsy, excisional biopsy or pericardial fluid cytology, to establish a definitive diagnosis.
  • A 60-year-old immunocompetent man who presented with superior vena cava syndrome secondary to a right atrial, primary cardiac diffuse large B cell lymphoma (non-Hodgkin's lymphoma) is described in the present article.
  • The patient had no clinical evidence of disseminated lymphoma and was successfully treated with prompt surgical excision of his atrial mass, followed by anthracycline-based chemotherapy.
  • The patient required multi-modality cardiac imaging to accurately identify and plan surgical excision of his cardiac lymphoma.
  • The therapeutic management and clinical and radio-logical features of primary cardiac lymphoma are reviewed.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Superior Vena Cava Syndrome / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Oct 15;80(8):1497-506 [9338475.001]
  • [Cites] Cardiovasc Pathol. 2009 Mar-Apr;18(2):92-9 [18402841.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1344-50 [17721189.001]
  • (PMID = 19536397.001).
  • [ISSN] 1916-7075
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2722499
  •  go-up   go-down


9. Sturm A, Noppeney R, Reimer J, Ross B, Baumgart D, Sundermann T, Sadony V, Gerken G: [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Dtsch Med Wochenschr; 2001 Mar 30;126(13):364-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection].
  • [Transliterated title] AIDS und Non-Hodgkin Lymphome--kardiale Erstmanifestation eines hochmalignen B-Zellymphoms nach 18 Jahren HIV-Infektion.
  • HISTORY AND FINDINGS: A 35-year-old man who, as a result of intravenous drug abuse, had become infected with HIV 18 years previously, was admitted with signs of right-heart failure.
  • DIAGNOSIS, TREATMENT AND COURSE: Endocarditis with atrial thrombi and recurrent pulmonary emboli was diagnosed and treated with antibiotics and anticoagulants.
  • Computed tomography of skull, thorax and abdomen did not demonstrate any significantly enlarged lymph nodes.
  • Exploratory thoracotomy revealed an infiltrating highly malignant centroblastic non-Hodgkin's lymphoma (NHL) of almost the entire free wall of the right atrium.
  • After two courses of chemotherapy (CHOP protocol) the size of the tumour had significantly decreased.
  • CONCLUSION: The differential diagnosis of a right atrial tumour can be difficult in patients with HIV or AIDS.
  • Even if the site is atypical and there is no lymphadenopathy, a lymphoma should be considered.
  • In case of doubt a histological diagnosis via an exploratory thoracotomy should be performed.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Echocardiography, Transesophageal. Heart Atria / pathology. Humans. Male. Prednisone / administration & dosage. Substance Abuse, Intravenous / complications. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332231.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Ozimek W, Wróblewska-Kałuzewska M, Gadomski A, Sopyło B, Rokicka-Milewska R, Jaranowska D, Ebinger K, Malec Z, Brzewski M: Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma. Med Sci Monit; 2000 Sep-Oct;6(5):1013-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma.
  • The case of a potentially life-threatening complication related to the use of implanted port device in a 8 year old Non-Hodgkin's Lymphoma patient receiving chemotherapy is described.
  • The device was inserted in early 1997 and used repeatedly for chemotherapy without any complications.
  • In late 1997 during routine screening for cardiac left ventricular function before re-introduction of chemotherapy, an abnormal 1.43 x 1.53 cm mass, consistent with a non-mobile thrombus was found in the right atrium.
  • The initial thrombolytic therapy with recombinant tissue plasmin activator (rt-PA) infused by a central venous catheter was combined with daily echocardiographic examination in order to assess both the timing and mode of thrombus resolution.
  • After 8 days systemic fibrinolytic therapy was discontinued as major hemorrhage from venipuncture sites occurred and the clot dissolution was not obtained.
  • The study evaluated the contribution of two-dimensional echocardiography (2D) in the follow-up of vascuport and other central venous catheter (CVC) location and early diagnosis of related complications such as thrombi.
  • The authors consider that pulmonary flow analyzed with Doppler echocardiography as a reliable, suitable and non-invasive method to evaluate increased pulmonary artery pressure in children with right atrial thrombi and probability of pulmonary microembolism or embolism.
  • As the incidence of right atrial thrombi is highly associated with the catheter tip position in the right atrium, in contrast to their positioning in the superior vena cava or in its junction with the right atrium, the authors recommend that special attention and effort should be given to placing of the catheter tip in the superior vena cava or in its junction with the right atrium avoiding the right atrium during the implantation procedure.
  • The surgical right atrium thrombus removal in patients with no clot dissolution despite systemic thrombolytic treatment underscores the importance of surgical therapy in treating this life-threatening complication of indwelling catheters.
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Child. Echocardiography, Doppler. Heart Atria / ultrasonography. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Pulmonary Circulation. Thrombolytic Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208448.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Kilickap S, Yavuz B, Aksoy S, Sahiner L, Dincer M, Harputluoglu H, Erman M, Aytemir K, Tokgozoglu L, Barista I: Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol; 2008;25(4):437-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
  • BACKGROUND: The addition of rituximab to doxorubicin-containing standard chemotherapy significantly improves response to therapy and reduces the risk of death in B-cell non-Hodgkin's lymphoma (NHL) patients.
  • METHODS: Patients who had been planned to receive CHOP or rituximab plus CHOP (R-CHOP) combination chemotherapy with a diagnosis of NHL were included in the study.
  • In all patients, systolic and diastolic parameters were measured by using conventional and pulsed-wave tissue Doppler echocardiography, which is more sensitive than conventional lead-dependent techniques, both before and in the sixth month of therapy.
  • None of the patients developed clinically evident congestive heart failure.
  • In both arms, tissue Doppler parameters of diastolic function such as lateral E and septal E velocity of mitral annulus decreased significantly after therapy (P < 0.001).
  • However, the decrease in diastolic function was similar in both arms (P > 0.05).
  • CONCLUSION: Both CHOP and R-CHOP cause diastolic dysfunction in the early period following their administration.
  • The addition of rituximab to CHOP chemotherapy does not significantly increase the risk of doxorubicin-induced cardiotoxicity during this period.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Lymphoma, Non-Hodgkin / drug therapy. Ventricular Dysfunction, Left / chemically induced
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Echocardiography, Doppler. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Risk Factors. Rituximab. Ventricular Function, Left / drug effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):167-73 [16029344.001]
  • [Cites] Haematologica. 2003 Jun;88(6):ECR22 [12801855.001]
  • [Cites] Cancer. 1979 Feb;43(2):465-71 [421174.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2313-20 [9667245.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1962-3 [10561242.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] South Med J. 2007 Mar;100(3):262-5 [17396729.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Am J Med. 1993 Feb;94(2):133-9 [8430709.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):47-58 [8644988.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Cancer. 1973 Aug;32(2):302-14 [4353012.001]
  • [Cites] Europace. 2005 May;7(3):227-30 [15878560.001]
  • [Cites] Cancer Treat Rev. 1976 Sep;3(3):111-20 [822941.001]
  • [Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Ann Oncol. 2005 May;16(5):798-804 [15774486.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1930 [12930732.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):203-4 [15061224.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1213-8 [3621107.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):2-7 [11552224.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4711-6 [15483015.001]
  • (PMID = 18415035.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Jantunen E, Hartikainen J: Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant; 2005 Dec;36(12):1077-82
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
  • We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT).
  • After the high-dose CY left atrial end-systolic area increased from 15.2+/-1.2 to 18.5+/-1.4 cm2 (P=0.001), left ventricular end-diastolic volume from 136.1+/-12.3 to 156.6+/-11.1 cm3 (P=0.04) and left ventricular end-systolic volume from 67.4+/-7.8 to 75.3+/-7.1 cm3 (P=0.018).
  • At the same time, plasma levels of NT-proBNP increased from 134.9+/-53.3 to 547.1+/-168.4 pmol/l (P=0.003) and NT-proANP from 481.1+/-105.5 to 1056.6+/-193.1 pmol/l (P=0.001), respectively.
  • To conclude, high-dose CY results in very acute cardiac toxicity characterised by enlargement of the heart chambers in NHL patients previously treated with anthracyclines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart / drug effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cardiovascular System / pathology. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Natriuretic Peptides / blood. Peptides / chemistry. Prospective Studies. Time Factors. Transplantation, Autologous. Ventricular Dysfunction, Left / diagnosis. Ventricular Function, Left

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247436.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Natriuretic Peptides; 0 / Peptides; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; BAEC protocol
  •  go-up   go-down


13. Konety SH, Wooldridge JE, Kerber RE: Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography. Echocardiography; 2006 Feb;23(2):147-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography.
  • We present the case of a 79-year-old man with an intracardiac mass, shown to be an aggressive large B-cell lymphoma by mediastinal aspiration, who had rapid regression of the tumor following one cycle of chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445735.001).
  • [ISSN] 0742-2822
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Visani G, Isidori A: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther; 2009 Mar;9(3):357-63
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
  • Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).
  • However, their clinical potential is limited by their cardiotoxic adverse effects, which include cardiomyopathy and congestive heart failure.
  • Liposomal doxorubicin has been developed with the aim of improving the therapeutic index of doxorubicin by reducing the drug's cardiotoxicity.
  • Nevertheless, liposomal conjugation of doxorubicin results in preferential distribution of the drug in the tumor compared with normal tissue, maintaining its anti-tumor efficacy.
  • Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with NHL either at diagnosis or at relapse.
  • The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in NHL might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275512.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 31
  •  go-up   go-down


15. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2008 Jul 1;26(19):3159-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Anthracycline-based chemotherapy, which improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly patients because of its cardiotoxicity.
  • We studied the cardiac effects of doxorubicin in a population-based sample of older patients with diffuse large B-cell lymphoma (DLBCL).
  • PATIENTS AND METHODS: Among patients age > or = 65 years diagnosed with DLBCL from 1991 to 2002 in the Surveillance, Epidemiology, and End Results-Medicare database, we developed logistic regression models of the associations of doxorubicin with demographic, clinical, and cardiac variables.
  • We then developed Cox proportional hazards models of the association between doxorubicin and subsequent congestive heart failure (CHF), taking predictors of CHF into account.
  • RESULTS: Of 9,438 patients with DLBCL, 3,164 (42%) received doxorubicin-based chemotherapy.
  • Any doxorubicin use was associated with a 29% increase in risk of CHF (95% CI, 1.02 to 1.62); CHF risk increased with number of doxorubicin claims, increasing age, prior heart disease, comorbidities, diabetes, and hypertension; hypertension intensified the effect of doxorubicin on risk of CHF (hazard ratio = 1.8; P < .01).
  • In the 8 years after diagnosis, the adjusted CHF-free survival rate was 74% in doxorubicin-treated patients versus 79% in patients not treated with doxorubicin.
  • CONCLUSION: Among patients receiving chemotherapy for DLBCL, those with prior heart disease were less likely than others to be treated with doxorubicin, and those who received doxorubicin were more likely than others to develop CHF.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiotoxins. Doxorubicin / adverse effects. Heart Diseases / chemically induced. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591554.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA94061; United States / NCRR NIH HHS / RR / T32 ULI RR024156
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cardiotoxins; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM: [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients]. Med Clin (Barc); 2010 Jan 30;134(2):72-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
  • [Transliterated title] Doxorrubicina liposomal no pegilada en combinación con ciclofosfamida, vincristina, prednisona y rituximab en el tratamiento de linfomas no hodgkinianos: estudio de 26 pacientes.
  • BACKGROUND AND OBJECTIVES: Non-pegylated liposomal doxorubicin is associated with lower cardiac toxicity than conventional doxorubicin, and for that reason it has been used in the treatment of non-Hodgkin's lymphoma (NHL) in old patients or patients with cardiac disease.
  • The objective of this study was to evaluate the efficacy and safety of chemotherapy schedules including non-pegylated liposomal doxorubicin in patients with NHL.
  • PATIENTS AND METHODS: Retrospective study of NHL patients treated with non-pegylated liposomal doxorubicin in two hospitals.
  • In each patient demographic data, clinical and biological variables, as well as therapy, response and toxicity were recorded.
  • The most frequent histological diagnosis was diffuse large B cell lymphoma (DLBCL, 20 patients).
  • The stage disease at diagnosis was III/IV in 19 (73%) patients whereas 12 (57%) of the 21 patients with DLBCL and grade 3 follicular lymphoma had a high-risk International Prognostic Index.
  • Three patients had a left ventricular ejection fraction lower than 50% at the time of starting treatment.
  • The most frequent cardiovascular risk factor was hypertension (50% of the patients) and 6 (23%) had previous heart disease.
  • In all cases non-pegylated liposomal doxorubicin was administered as part of the R-COMP schedule (rituximab, cyclophosphamide, vincristin, non-pegylated liposomal doxorubicin and prednisone), in 20 cases (73%) as first-line treatment and in the remaining 6 as salvage therapy.
  • Two patients died after the first cycle of chemotherapy (one because of sudden death and the other due to disease progression).
  • Eleven (61%) out of the 18 patients receiving R-COMP as first-line therapy achieved a complete response (CR), 5 (28%) achieved partial response (PR) and 2 showed progression.
  • Only one out of the 6 patients receiving R-COMP as salvage therapy achieved CR, whereas 3 had PR and 2 did not respond.
  • Grade 3 or 4 neutropenia was observed in 11 (46%) patients and febrile neutropenia in 10 (42%), while only one patient developed grade 4 thrombocytopenia.
  • CONCLUSIONS: In this cohort of patients, most of them old and with cardiovascular risk factors, the administration of non-pegylated liposomal doxorubicin as part of R-COMP regimen was effective and safe.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19913261.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


17. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW: A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol; 2005 Jun;129(5):597-606
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index.
  • Over 60% of patients aged over 70 years, diagnosed with non-Hodgkin's lymphoma (NHL) in the Netherlands have serious comorbidity.
  • We studied the independent influence of comorbidity on choice of treatment, dose reductions, treatment-related toxicity and prognosis, using data from a random sample of 381 patients from the population-based Eindhoven Cancer Registry.
  • About 45% of patients over 60 years of age with NHL had high impact comorbidity at the time of cancer diagnosis.
  • The proportion of patients with aggressive NHL who received chemotherapy decreased from 85% in patients aged 40-60 years to 70% in those over 60 years.
  • About 65% of systematically treated patients with aggressive NHL suffered from treatment-related toxicity.
  • Dose reductions are frequently unavoidable for patients with severe comorbidity, poor performance status or chemotherapy-related toxicity.
  • Whether the less frequent prescription of (full dose) chemotherapy for patients with advanced age and/or with comorbidity is justified remains a question for debate.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Heart Diseases / complications. Kidney Failure, Chronic / complications. Lymphoma, Non-Hodgkin / complications. Neoplasms / complications. Pulmonary Disease, Chronic Obstructive / complications
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Female. Humans. Logistic Models. Male. Middle Aged. Netherlands. Prognosis. Survival Rate. Treatment Outcome


18. Caggiano V, Morrison VA, Fridman M, Delgado DJ: A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):6100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer.
  • : 6100 Background: Reduction of chemotherapy dose intensity is common among patients receiving treatment for non-Hodgkin's lymphoma (NHL) and breast cancer.
  • A recent publication suggests that neutropenia is a cause of dose modifications, and that maintaining chemotherapy dose intensity in the initial cycles may be associated with improved outcomes.
  • We evaluated possible risk factors associated with delivery of reduced chemotherapy dose intensity in the first 3 cycles of treatment among a sample of patients with NHL or breast cancer.
  • METHODS: A historical case series of 1617 patients (704 NHL and 913 early-stage breast cancer) who received initial chemotherapy at 16 community and academic oncology practices between 1991 and 1999 were studied.
  • RESULTS: 427 of 1617 patients (26%) received reduced ARDI within the first 3 cycles of chemotherapy.
  • Factors significantly associated with delivery of reduced ARDI in a multiple logistic regression model included age greater than or equal to 65 years (odds ratio [OR] 2.4; 95% CI 1.8-3.2), presence of heart, renal, or hepatic comorbidity (OR 2.2; 95% CI 1.6-3.2), low body surface area (OR 1.3; 95% CI 1.1-1.7), and no preemptive growth factor in cycle 1 (OR 1.7; 95% CI 1.0-2.6).
  • CONCLUSIONS: Increased age, comorbidity (heart, renal or hepatic), low body surface area, and no preemptive growth factor in cycle 1 were associated with increased risk for delivery of reduced chemotherapy dose intensity in cycles 1 through 3 after controlling for differences in diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Voelker MD, Chrischilles EA, Wright KB, Link BK, Park TR, Delgado DJ: Factors associated with first course chemotherapy among older patients with newly diagnosed non-Hodgkin's lymphoma: National SEER-Medicare study. J Clin Oncol; 2004 Jul 15;22(14_suppl):6118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with first course chemotherapy among older patients with newly diagnosed non-Hodgkin's lymphoma: National SEER-Medicare study.
  • : 6118 Background: Chemotherapy (CT) is indicated for some non-Hodgkin's lymphoma (NHL) patients (pts) with initial diagnosis.
  • METHODS: Using the National Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, we identified newly diagnosed NHL pts (1991-1999), age ≥66 years, with continuous non-HMO Medicare part A and B benefits.
  • First course CT was defined as a claim within 5 months of diagnosis (Dx) and whether cyclophosphamide with either doxorubicin or mitoxantrone (CH/CN) was given was determined.
  • Among all 15,014 pts, factors multivariately associated (p≤0.05) with receiving CT were: diffuse large cell (DLC) histology, advanced (adv) stage, younger age, white race, Charlson comorbidity index (CCI) =0, no renal disease, no anemia, no radiation therapy, SEER site and Dx year.
  • Multivariately, receipt of CH/CN was significantly (p≤0.05) less likely with advancing age, CCI>0, anemia, heart disease, and radiation therapy.
  • Of particular interest was the rate (only 68%) of CT use in adv stage DLC lymphoma.
  • CONCLUSIONS: Nonclinical factors (younger age, white race, Dx year and SEER site) and clinical factors (DLC histology, adv stage, no radiation therapy and less comorbidity) were independently associated with receiving first course CT in this population-based study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • [Transliterated title] Troubles du rythme et de la conduction révélateurs d'une localisation cardiaque de lymphome malin non hodgkinien. A propos de 2 cas.
  • Primary cardiac lymphoma is very rare.
  • Clinical symptoms of cardiac involvement are rare, explaining the usual post-mortem diagnosis.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Electrocardiography. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Manojkumar R, Sharma A, Grover A: Secondary lymphoma of the heart presenting as recurrent syncope. Indian Heart J; 2001 Mar-Apr;53(2):221-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoma of the heart presenting as recurrent syncope.
  • Left cervical lymph node biopsy confirmed the diagnosis of non-Hodgkin's lymphoma.
  • The tumor resolved completely with chemotherapy without surgical intervention.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Syncope / etiology
  • [MeSH-minor] Amiodarone / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Child. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Humans. Male. Prednisolone. Recurrence. Tachycardia, Ventricular / etiology. Tomography, X-Ray Computed. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Fainting.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11428484.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; N3RQ532IUT / Amiodarone; VAP-cyclo protocol
  •  go-up   go-down


22. Wach M, Dmoszyńska A, Wasik-Szczepanek E, Skomra D: [Unusual cases of non-Hodgkin's lymphomas--case reports]. Pol Arch Med Wewn; 2000 Mar-Apr;103(3-4):205-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual cases of non-Hodgkin's lymphomas--case reports].
  • We describe 4 cases of non-Hodkin's lymphomas that were interesting because of their curiosal clinical courses and spontaneous complete remissions during the course of high malignancy lymphoma.
  • We present three of them for the first time in Poland.
  • The diagnosis of B-cell lymphoma was established at histopathological examination of the postoperative material.
  • Co60--therapy of these region was applied after the operation with good response.
  • During the hospitalization haemolytic anaemia of unknown origin, thrombocytopoenia, splenomegaly, fever and rising acute insufficiency of kidneys, heart, liver and CNS were occurred.
  • The diagnosis of intravascular lymphoma was established at postmortem examination.
  • Case 3: a 51-year old woman was admitted to the hospital with diagnosis: anaplastic non-Hodgkin lymphoma B-cell type high malignancy established after the double histopathological examination of lymph nodes and biopsy of the lung.
  • She died after 6 months since the beginning of the relapse despite intensive chemotherapy.
  • The diagnosis: chronic prolymphocytic leukaemia was established.
  • The patient died despite intensive therapy due to rising progressive multiorgan failure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Brain Neoplasms / diagnostic imaging. Brain Neoplasms / surgery. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11236249.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


23. Tanaka J, Takamoto S, Ryu T, Ichikawa K, Masuo M, Saito T: [Primary cardiac lymphoma: a case report]. J Cardiol; 2002 Nov;40(5):225-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: a case report].
  • Transvenous biopsy failed to obtain sufficient specimens for the histological diagnosis.
  • The tumor progressed rapidly and heart failure was intractable.
  • The diagnosis was primary cardiac lymphoma on the basis of elevated soluble interleukin-2 receptor and solitary accumulation of gallium-67 in the heart.
  • Chemotherapy was immediately started.
  • After two courses of chemotherapy, the intracardiac tumor disappeared.
  • Needle biopsy disclosed diffuse B-cell non-Hodgkin's malignant lymphoma.
  • Early diagnosis and immediate chemotherapy are important for the treatment of primary cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Echocardiography. Female. Gallium Radioisotopes. Heart Failure / etiology. Humans. Magnetic Resonance Imaging. Receptors, Interleukin-2 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12463097.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Receptors, Interleukin-2
  •  go-up   go-down


24. Boccardi L, Pino PG: [Primary lymphoma of the right atrium: a case report]. Ital Heart J Suppl; 2004 Jun;5(6):487-91
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the right atrium: a case report].
  • The cases described in the literature are recently increased thanks to the employment of the new diagnostic methodologies (computed tomography, nuclear magnetic resonance, transesophageal echocardiography).
  • Particularly the primitive lymphoma, non-HIV correlated, is very rare (< 1.5% of all cardiac tumors), but it is treatable when appropriately diagnosed.
  • The examination of the tissue obtained by transvenous intracardiac biopsy with transesophageal echocardiography guidance revealed high grade non-Hodgkin's lymphoma of B-cell lineage.
  • The patient achieved complete tumor remission after treatment with standard chemotherapy.
  • This case demonstrates that early diagnosis might contribute to a better prognosis for patients with malignant lymphoma of the heart.
  • [MeSH-major] Heart Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Therapy, Combination. Echocardiography, Doppler. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Heart Atria / pathology. Humans. Male. Middle Aged. Remission Induction. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15471154.001).
  • [ISSN] 1129-4728
  • [Journal-full-title] Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology
  • [ISO-abbreviation] Ital Heart J Suppl
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Antoniades L, Eftychiou C, Petrou PM, Bagatzounis A, Minas M: Primary cardiac lymphoma: case report and brief review of the literature. Echocardiography; 2009 Feb;26(2):214-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma: case report and brief review of the literature.
  • Primary cardiac lymphoma is defined as a non-Hodgkin's lymphoma mainly located in the heart and/or the pericardium.
  • Common manifestations are pericardial effusion and heart failure.
  • Diagnosis is usually late and prognosis is poor.
  • We report a case of a patient with a large primary cardiac lymphoma who presented with chest pain and negative T-waves in electrocardiogram.
  • Tissue biopsy showed a high-grade B-cell diffuse lymphocytic lymphoma.
  • The patient was treated with chemotherapy and radiation with complete remission and prolonged survival.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Aged. Chest Pain / etiology. Diagnosis, Differential. Echocardiography. Electrocardiography. Follow-Up Studies. Heart Atria / ultrasonography. Heart Ventricles / ultrasonography. Humans. Male. Rare Diseases. Remission Induction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138175.001).
  • [ISSN] 1540-8175
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


26. Porcar Ramells C, Clemente González C, García Parés D, Guardia Sánchez R, Pérez Ayuso MJ, García-Bragado Dalmau F: [Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature]. An Med Interna; 2002 Jun;19(6):305-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
  • [Transliterated title] Linfoma cardiaco primario: diagnóstico citológico y tratamiento con respuesta a poliquimioterapia y a autotrasplante de precursores hematopoyéticos. Presentación de un caso y revisión de la literatura.
  • The primary cardiac lymphoma (PCL) is an extremely infrequent tumor suffered by immunocompetent patients with a difficult diagnosis and slow progress leading to a serious prognosis and few therapeutically possibilities.
  • It's a primary-cardiac non-Hodgkin's lymphoma (NHL) in a patient of 46-year-old, immunocompetent, who started with a congestive heart failure and atrial flutter.
  • Some examinations were carried out such as a transesophageal echocardiography (TEE), a computed tomography (TC) and a magnetic resonance imaging (MRI) and an intracardiac tumor placed in the interauricular septum was detected.
  • The diagnosis was based on a pleural fluid cytological examination.
  • It was decided to follow a chemotherapy treatment and the autologous peripheral blood stem cells transplantation was carried out.
  • The patient remains in full remission thirty-six months after diagnosis and twenty-nine months after the autotransplant.
  • Our clinical experience indicated that an early and accurate diagnosis combined with the appropriate and aggressive antilymphoma therapy can thus help in obtaining a long survival in patients with PCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / diagnosis. Heart Septum. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Atrial Flutter / etiology. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Echocardiography, Transesophageal. Etoposide / administration & dosage. Heart Failure / etiology. Humans. Hydrocortisone / administration & dosage. Immunocompetence. Injections, Spinal. Magnetic Resonance Imaging. Male. Melphalan / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Pleural Effusion / etiology. Prednisone / administration & dosage. Remission Induction. Tomography, X-Ray Computed. Transplantation Conditioning. Transplantation, Autologous. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12152391.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; BEAM regimen; CHOP protocol
  • [Number-of-references] 56
  •  go-up   go-down


27. Bergler-Klein J, Knoebl P, Kos T, Streubel B, Becherer A, Schwarzinger I, Maurer G, Binder T: Myocardial involvement in a patient with Burkitt's lymphoma mimicking hypertrophic cardiomyopathy. J Am Soc Echocardiogr; 2003 Dec;16(12):1326-30
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial involvement in a patient with Burkitt's lymphoma mimicking hypertrophic cardiomyopathy.
  • Burkitt's lymphoma is a highly aggressive type of non-Hodgkin's lymphoma frequently associated with extranodal or abdominal manifestations.
  • We report the case of a young woman with generalized Burkitt's lymphoma, initially presenting with signs and symptoms of central nervous system involvement.
  • These abnormalities resolved after high-intensity chemotherapy with a modified B-cell acute lymphoblastic leukemia (B-ALL) protocol.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cardiomyopathy, Hypertrophic / diagnosis. Heart Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14652615.001).
  • [ISSN] 0894-7317
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Jamet B, Saade YA, Torossian F, Bonfils L, Elaerts J: [Cardiac lymphoma disclosed by ischemic accident. A case report]. Ann Cardiol Angeiol (Paris); 2000 Sep;49(6):343-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac lymphoma disclosed by ischemic accident. A case report].
  • [Transliterated title] Lymphome cardiaque révélé par un accident ischémique. A propos d'un cas.
  • We report on the detection of a primitive cardiac lymphoma revealed by a cerebral vascular accident in a context of deterioration of the general state with fever.
  • The diagnosis of the cerebral vascular accident was verified by the brain scan.
  • The echocardiography, in particular the transesophageal ultrasound, suggested the diagnosis of cardiac lymphoma due to the existence of an inhomogeneous multilobar mass invading the right ventricle and largely encompassing the right auricle.
  • The histologic diagnosis of a malignant non-Hodgkin's lymphoma of type B malignancy was confirmed by anatomopathology.
  • The evolution was, unfortunately, rapidly unfavorable, with the patient dying in a state of cerebral suffering despite a combination treatment of chemotherapy and radiotherapy.
  • [MeSH-major] Brain Ischemia / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555345.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Chalabreysse L, Berger F, Loire R, Devouassoux G, Cordier JF, Thivolet-Bejui F: Primary cardiac lymphoma in immunocompetent patients: a report of three cases and review of the literature. Virchows Arch; 2002 Nov;441(5):456-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma in immunocompetent patients: a report of three cases and review of the literature.
  • Primary cardiac lymphoma is an extranodal non-Hodgkin's lymphoma exclusively located in the heart and/or pericardium, extremely rare in immunocompetent patients, and more frequent in immunodepressed patients.
  • We present 3 retrospectives cases of primary cardiac lymphoma in immunocompetent patients and review 35 cases reported in the literature.
  • Primary cardiac lymphoma presented with constitutional symptoms in two cases and superior vena caval syndrome in one case.
  • Diagnosis of a tumor mass was made in all cases by transthoracic echocardiography.
  • Primary cardiac lymphoma arose in the heart right chambers in two cases.
  • Histological diagnoses, obtained after thoracotomy, were diffuse large B-cell lymphoma in two cases, and Burkitt's lymphoma in one case.
  • All three cases received chemotherapy, combined with radiotherapy in one patient.
  • Of our patients, 2 are alive and asymptomatic 12 months and 33 months after diagnosis.
  • In conclusion, diagnosis of primary cardiac lymphoma is difficult due to non-specific clinical manifestations and should be considered in patients with a cardiac mass sometimes with pericardial effusion.
  • The only effective treatment is chemotherapy, but prognosis remains poor.
  • [MeSH-major] Burkitt Lymphoma / pathology. Heart Neoplasms / pathology. Immunocompetence. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12447675.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 42
  •  go-up   go-down


30. Brueck M, Bandorski D, Stahl U, Kramer W: [Superior vena cava syndrome by cardiac tumor]. Med Klin (Munich); 2009 Jan 15;104(1):52-7
Genetic Alliance. consumer health - Superior vena cava syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sekundäres kardiales Non-Hodgkin-Lymphom als Differentialdiagnose des Vena-cava-superior-Syndroms.
  • There were neither cardiovascular risk factors nor drug medication.
  • Physical examination revealed a dilatation of the neck veins with a present Kussmaul sign and a diastolic murmur at the left lower sternal border.
  • Thoracic computed tomography confirmed the tumor mass and showed enlargement of mediastinal lymph nodes.
  • The immunohistology of the specimen revealed non-Hodgkin's lymphoma.
  • The patient subsequently received a chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
  • After the third cycle of therapy, both tumor and pericardial effusion had disappeared.
  • Tissue biopsy is warranted to guide diagnosis and therapy.
  • [MeSH-major] Heart Atria. Heart Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Superior Vena Cava Syndrome / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Biopsy. Diagnosis, Differential. Echocardiography. Echocardiography, Transesophageal. Electrocardiography. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Pericardial Effusion / drug therapy. Pericardial Effusion / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142595.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


31. Fuchida S, Yamada N, Uchida R, Okano A, Okamoto M, Ochiai N, Shimazaki C: Malignant lymphoma presenting as a cardiac tumor and superior vena caval syndrome successfully treated by haploidentical stem cell transplantation. Leuk Lymphoma; 2005 Oct;46(10):1517-21
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma presenting as a cardiac tumor and superior vena caval syndrome successfully treated by haploidentical stem cell transplantation.
  • A 16 year-old male with B-cell non-Hodgkin's lymphoma presenting as a cardiac tumor and superior vena caval (SVC) syndrome received a haploidentical stem cell transplant (SCT) from his mother after conventional and salvage chemotherapy.
  • He received additional radiation therapy for the residual tumor and is alive and well on day 640 after transplantation.
  • Malignant lymphoma presenting as a cardiac tumor, including primary cardiac lymphoma, is rare.
  • Although many reports have shown the poor prognosis of cardiac lymphoma, our case suggests that allogeneic haploidentical SCT might be useful for the treatment of aggressive cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Stem Cell Transplantation. Superior Vena Cava Syndrome / complications. Superior Vena Cava Syndrome / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194899.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM: Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma; 2002 Feb;43(2):423-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.
  • We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region.
  • Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) producing sheets of cells with an organoid distribution.
  • These studies were supportive of a diagnosis of a plasmablastic lymphoma.
  • Treatment with CHOP chemotherapy with filgrastim support was begun which resulted in another remission.
  • Plasmablastic lymphoma is now reported in some studies to account for 2.6% of all HIV-related NHL.
  • Therapy with standard regimens has variable response.
  • The regression of disease after resumption of HAART therapy alone in this patient suggests that HAART has an important role in the treatment of lymphoma in the HIV infected patient.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. HIV Infections / complications. HIV Infections / drug therapy. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Remission Induction

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999580.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


33. Lin YS, Chu PH, Kuo MC, Jung SM, Lim KE, Kuo CT, Shih LY: Use of a B-type natriuretic peptide in evaluating the treatment response of a relapsed lymphoma with cardiac involvement. Int J Hematol; 2006 Jan;83(1):44-6
MedlinePlus Health Information. consumer health - Heart Valve Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a B-type natriuretic peptide in evaluating the treatment response of a relapsed lymphoma with cardiac involvement.
  • A 50-year-old woman received a diagnosis of diffuse large B-cell non-Hodgkin's lymphoma in 2000 and achieved complete remission.
  • In April 2004, echocardiography and computed tomography examinations identified a tumor attached to the tricuspid valve and protruding within the right atrium.
  • Bone marrow and lymph node biopsies showed a relapse of large cell lymphoma.
  • The patient had a markedly elevated level of B-type natriuretic peptide (BNP) but a normal level of cardiac troponin I.
  • The follow-up evaluation of the BNP level after chemotherapy showed that it had returned to within normal limits, and an echocardiogram showed regression of the tumor.
  • Use of the BNP level as a monitor in the treatment of cardiac lymphoma has never been reported.
  • This article is the first to report the use of BNP monitoring before and after chemotherapy to evaluate a patient with an unusual relapsed lymphoma with cardiac involvement.
  • [MeSH-major] Heart Neoplasms / blood. Heart Valve Diseases / blood. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood. Natriuretic Peptide, Brain / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Heart J. 2004 Nov;148(5):895-902 [15523324.001]
  • [Cites] Ann Hematol. 1998 Sep;77(3):139-41 [9797085.001]
  • [Cites] Am Heart J. 2004 Sep;148(3):518-23 [15389242.001]
  • [Cites] Cardiovasc Res. 2001 Aug 15;51(3):442-9 [11476734.001]
  • [Cites] Circulation. 2004 Jun 29;109 (25):3176-81 [15184280.001]
  • [Cites] Int J Clin Pract. 2004 Jun;58(6):564-7 [15311555.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1610-7 [7477198.001]
  • [Cites] Circulation. 2002 Jul 23;106(4):416-22 [12135939.001]
  • [Cites] N Engl J Med. 2004 Feb 12;350(7):647-54 [14960741.001]
  • [Cites] Int J Clin Pract. 2004 Mar;58(3):306-9 [15117101.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):161-7 [12124404.001]
  • [Cites] N Engl J Med. 1998 Jul 30;339(5):321-8 [9682046.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1280-7 [7657802.001]
  • (PMID = 16443551.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


34. Xinjia F, Matano S, Amitani S, Terahata S, Furusyo H, Yamamoto M, Sugimoto T: [Low-dose etoposide in a patient with adult T-cell leukemia/lymphoma who had severe complications]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1269-72
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-dose etoposide in a patient with adult T-cell leukemia/lymphoma who had severe complications].
  • The histopathologic diagnosis of the biopsied lymph node was diffuse pleomorphic type non-Hodgkin's lymphoma with T-cellular phenotype, and the patient was referred to our department.
  • She had human T-lymphotropic virus type I seropositivity, and PCR of the pX lesion disclosed a monoclonal band.
  • She was ultimately diagnosed as having adult T-cell leukemia/lymphoma (ATL/L, stage IV).
  • She continued to receive intermittent LD-ETP, but she developed pneumonia in June 2000, and died in August 2000.
  • These findings suggest that LD-ETP is a well tolerable and effective treatment in patients with ATL/L even if there are severe complications.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Etoposide / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Aged. Aneurysm, Dissecting / complications. Aortic Aneurysm / complications. Cerebral Infarction / complications. Female. Heart Failure / complications. Humans. Hypertension, Pulmonary / complications. Pulmonary Embolism / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579638.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


35. Maeder M, Spieler P, Krapf R, Diethelm M: Cytologically malignant lymphoid pericardial effusion with benign clinical outcome. Swiss Med Wkly; 2005 Jun 25;135(25-26):377-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Isolated malignant pericardial effusion is a manifestation of primary cardiac lymphoma (PCL) and primary effusion lymphoma (PEL), rare types of non-Hodgkin's lymphoma (NHL).
  • The diagnosis is based on different cytological methods and analyses including DNA-image cytometry (ICM-DNA).
  • Although in neither of the two patients systemic chemotherapy was administered, both were free of cancer after a follow-up of ten and nine years respectively.
  • It seems that DNA-aneuploidy may be not absolutely specific for the detection of malignant lymphoid cells in pericardial fluid.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Pericardial Effusion / diagnosis
  • [MeSH-minor] Aged. Aneuploidy. Cardiac Tamponade / etiology. Female. Humans. Image Cytometry. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106328.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP: Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation; 2004 Feb 15;77(3):431-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Abdominal-pelvic LPD was identified in 19 of 603 adult patients who underwent lung or heart-lung transplantation at Barnes-Jewish Hospital between July 1, 1988 and December 31, 2001.
  • The median time from transplantation to the onset of LPD was 5.8 years.
  • The time to diagnosis of LPD was significantly shorter for Epstein-Barr virus (EBV)-seronegative than for EBV-seropositive recipients (median, 175 vs. 2255 days; log-rank, P<0.001).
  • Seventeen cases were non-Hodgkin's lymphomas, one was a Burkitt's lymphoma, and one was an atypical lymphoid proliferation.
  • Immunosuppressive therapy was decreased in all patients.
  • Eleven underwent surgical resection, and nine received chemotherapy.
  • The median time from the diagnosis of LPD to death was 68 days.
  • This form of LPD is most frequently a non-Hodgkin's lymphoma, and despite aggressive therapy, the prognosis is poor.
  • [MeSH-minor] Burkitt Lymphoma / etiology. Dose-Response Relationship, Drug. Epstein-Barr Virus Infections / complications. Female. Gastrointestinal Diseases / etiology. Humans. Immunosuppressive Agents / administration & dosage. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14966421.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


37. Allred JD, McElderry HT, Doppalapudi H, Yamada T, Kay GN: Biventricular ICD implantation using the iliofemoral approach: providing CRT to patients with occluded superior venous access. Pacing Clin Electrophysiol; 2008 Oct;31(10):1351-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 32-year-old woman with a history of nonischemic dilated cardiomyopathy, left bundle branch block, left ventricular ejection fraction of 0.15, and New York Heart Association Class III congestive heart failure, despite optimal medical treatment, was referred for cardiac resynchronization therapy with implantation of an implantable cardioverter defibrillator.
  • The patient had prior chemotherapy for non-Hodgkin's lymphoma and was shown to have chronic total occlusion of the superior vena cava (SVC) by magnetic resonance imaging.
  • We conclude that the iliofemoral approach allows transvenous implantation of cardiac resynchronization therapy in patients with superior vena cava occlusion.
  • [MeSH-major] Defibrillators, Implantable. Heart Failure / complications. Heart Failure / prevention & control. Pacemaker, Artificial. Prosthesis Implantation / methods. Superior Vena Cava Syndrome / complications. Superior Vena Cava Syndrome / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Pacemakers and Implantable Defibrillators.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18811820.001).
  • [ISSN] 1540-8159
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A: Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol; 2002 May;117(2):379-86
Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study included 55 patients (18 with non-Hodgkin's lymphoma, 10 with acute lymphoblastic leukaemia, eight with acute myeloid leukaemia, five with chronic myeloid leukaemia, four with chronic lymphocytic leukaemia, four with multiple myeloma, three with myelodysplastic syndrome, two with myelofibrosis and one with thalassemia) who developed PCP.
  • Twelve patients (22%) developed PCP despite protective isolation in a laminar airflow room.
  • The most frequent symptoms were: fever (86%), dyspnoea (78%), non-productive cough (71%), thoracic pain (14%) and chills (5%); a severe hypoxaemia was present in 39 patients (71%).
  • Chest radiography or computerized tomography showed interstitial infiltrates in 34 patients (62%), alveolar infiltrates in 12 patients (22%), and alveolar-interstitial infiltrates in nine patients (16%).
  • The diagnosis was made in two patients at autopsy.
  • All patients except one started a specific treatment (52 patients trimethroprim/sulphamethoxazole, one pentamidine and one dapsone).
  • Sixteen patients (29%) died of PCP within 30 d of diagnosis.
  • Multivariate analysis showed that prolonged steroid treatment (P < 0.006) and a radiological picture of diffuse lung involvement (P < 0.003) were negative diagnostic factors.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Anti-Infective Agents / therapeutic use. Bronchoalveolar Lavage Fluid / microbiology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / microbiology. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / microbiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / microbiology. Leukemia, Myeloid / mortality. Lung / radiography. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / microbiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / microbiology. Multiple Myeloma / mortality. Multivariate Analysis. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / microbiology. Myelodysplastic Syndromes / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / microbiology. Primary Myelofibrosis / mortality. Retrospective Studies. Thalassemia / drug therapy. Thalassemia / microbiology. Thalassemia / mortality. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972521.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  •  go-up   go-down


39. Carver JR, Nasta S, Chong EA, Stonecypher M, Wheeler JE, Ahmadi T, Schuster SJ: Myocarditis during lenalidomide therapy. Ann Pharmacother; 2010 Nov;44(11):1840-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocarditis during lenalidomide therapy.
  • OBJECTIVE: To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma.
  • CASE SUMMARY: An 85-year-old woman with recurrent follicular lymphoma was treated with lenalidomide 10 mg daily and low-dose dexamethasone 8 mg once weekly in a clinical trial.
  • Within 17 days of starting lenalidomide and dexamethasone, she developed symptoms and signs of congestive heart failure.
  • Postmortem examination of the heart confirmed the absence of coronary artery disease, and histopathological examination of the myocardium revealed a diffuse lymphocytic/eosinophilic inflammatory infiltrate with associated acute and chronic myocardial injury affecting all 4 chambers of the heart, consistent with myocarditis.
  • DISCUSSION: Lenalidomide is an immunomodulatory agent derived from thalidomide and is approved for the treatment of multiple myeloma and myelodysplastic syndromes.
  • CONCLUSIONS: Our findings suggest that lenalidomide may be a cause of drug-induced myocarditis.
  • When patients treated with lenalidomide present with signs and symptoms of heart failure in the absence of other obvious causes, lenalidomide hypersensitivity should be considered in the differential diagnosis and a myocardial biopsy should be considered when other common causes of heart failure have been excluded.
  • A reasonable management approach is drug discontinuation and early institution of corticosteroid therapy.
  • An objective causality assessment, using the Naranjo probability scale, revealed that the adverse drug event was probable.
  • [MeSH-minor] Aged, 80 and over. Autopsy. Dexamethasone / therapeutic use. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Multiple Organ Failure / etiology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876827.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


40. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • Thrombotic thrombocytopenic purpura and thrombosis resulting from protein S deficiency are relatively rare complications of HIV in the United States in patients taking HAART, but are frequent in the developing world where these drugs are not available.
  • Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads.
  • This review will examine and discuss the diagnosis and management of the hematologic complications of HIV.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down






Advertisement